MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pardridge, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pardridge, W. M.
Molecular Interventions 3:90-105 (2003)
© 2003 American Society of Pharmacology and Experimental Therapeutics

Review

BLOOD-BRAIN BARRIER DRUG TARGETING: THE FUTURE OF BRAIN DRUG DEVELOPMENT

William M. Pardridge

Department of Medicine UCLA School of Medicine Los Angeles, CA 90024


The development of new drugs for the brain has not kept pace with progress in the molecular neurosciences, because the majority of new drugs discovered do not cross the blood-brain barrier (BBB). Although approximately 100% of large-molecule drugs do not cross the BBB, the problem is nearly as severe for small-molecule drugs—greater than 98% of small-molecule drugs do not cross the BBB. Despite this situation, no pharmaceutical company in the world today has a BBB drug-targeting program. Nevertheless, BBB drug targeting technology can be built around a knowledge base of the endogenous transporters within the brain capillary endothelium, which forms the BBB in vivo.




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
D. S. Miller, B. Bauer, and A. M. S. Hartz
Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy
Pharmacol. Rev., June 1, 2008; 60(2): 196 - 209.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Kim, R. N. Fariss, C. Zhang, S. B. Robinson, M. Thill, and K. G. Csaky
Mapping of the Neonatal Fc Receptor in the Rodent Eye
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 2025 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. F. Deeken and W. Loscher
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Clin. Cancer Res., March 15, 2007; 13(6): 1663 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
B.-S. Ding, T. Dziubla, V. V. Shuvaev, S. Muro, and V. R. Muzykantov
Advanced drug delivery systems that target the vascular endothelium.
Mol. Interv., April 1, 2006; 6(2): 98 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. O. Noble, M. T. Krauze, D. C. Drummond, Y. Yamashita, R. Saito, M. S. Berger, D. B. Kirpotin, K. S. Bankiewicz, and J. W. Park
Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy.
Cancer Res., March 1, 2006; 66(5): 2801 - 2806.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. K. Mahata, N. R. Mahapatra, M. Mahata, T. C. Wang, B. P. Kennedy, M. G. Ziegler, and D. T. O'Connor
Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo: DEMONSTRATION BY A NOVEL TRANSGENIC PROMOTER/PHOTOPROTEIN REPORTER AND INHIBITION OF SECRETION AND TRANSCRIPTION BY THE CHROMOGRANIN A FRAGMENT CATESTATIN
J. Biol. Chem., August 22, 2003; 278(34): 32058 - 32067.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.